CLINICAL_TRIALS
withdrawal
· 2014-10-27
Clinical Trial Update: Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes [Phase 3]
Summary
A Phase 3 trial comparing empagliflozin to sitagliptin in patients with Type 2 diabetes has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: WITHDRAWN